This is a preview of subscription content, log in via an institution to check access.
References
Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and meta-analysis. JAMA 1997, 277:739–745.
Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326–1331.
The SOLVD Investigators: Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 330:152–157.
Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.
Rights and permissions
About this article
Cite this article
Siragy, H.M. Clinical Trials Report. Current Science Inc 5, 293–294 (2003). https://doi.org/10.1007/s11906-003-0036-7
Issue Date:
DOI: https://doi.org/10.1007/s11906-003-0036-7